Radiopharmaceutical company Cyclopharm (ASX: CYC) has announced four management appointments.
Accoridng to managing firector and CEO, James McBrayer, “We have added a group of very high‐quality individuals to our team which will significantly strengthen our global compliance, sales and service capabilities, supporting the next phase of growth at Cyclopharm.”
“Specifically, we have greatly enhanced our quality and compliance capabilities through the hiring of Dr Mark Doverty to lead our global regulatory compliance and clinical research efforts," he continued.
"As part of our leadership team, Mark will leverage his expertise and track record as the former Head of the Office of Manufacturing Quality at the Australian Government’s Therapeutic Goods Administration to ensure our products and manufacturing practices remain at the forefront of regulatory best practice.
"Mark will also be responsible for ensuring our research efforts continue to support our entry into new markets for Technegas and enhance our sales into existing markets as clinical applications evolve.”
Mr McBrayer said, “As we have previously discussed, the US market is a significant near‐term opportunity to rapidly grow our sales of Technegas. As we approach the anticipated US FDA approval to commence marketing Technegas in the USA, we have focused on ensuring Cyclopharm has the right people, capabilities and processes to quickly take advantage of this opportunity, while continuing to grow our sales and service capabilities in existing markets.
“The new hires, announced today, will support our goal of delivering initial sales and high‐quality customer service in the United States market in 2020 as well as driving the company’s strategy in the use of TechnegasTM in indications beyond pulmonary embolism throughout the 57 countries where Technegas is currently sold.”
Other appointments include Niamh McAree as head of Quality and Regulatory, Sally‐Ann Cornelius as head of Sales and Chris Quinn as head of Service.